Figure 1 | Scientific Reports

Figure 1

From: A Nomogram for Predicting the Benefit of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Hepatocellular Carcinoma

Figure 1

Kaplan–Meier survival curves for patients with hepatocelluar carcinoma (HCC) who received adjuvant CIK cell treatment (n = 511) or surgery alone (n = 520).

(A) Actuarial overall survival (OS) grouped by cytokine-induced killer (CIK) cells. (B) Actuarial progression-free survival (PFS) grouped by CIK cells. The log-rank test showed a significantly higher OS and PFS rate in the CIK group than the control group.

Back to article page